• LAST PRICE
    0.7362
  • TODAY'S CHANGE (%)
    Trending Down-0.0273 (-3.5756%)
  • Bid / Lots
    0.7400/ 4
  • Ask / Lots
    0.7590/ 60
  • Open / Previous Close
    0.7733 / 0.7635
  • Day Range
    Low 0.7310
    High 0.7733
  • 52 Week Range
    Low 0.6786
    High 5.9500
  • Volume
    521,794
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.7635
TimeVolumeSPRB
09:32 ET112470.756
09:34 ET26990.756
09:36 ET9000.7583
09:38 ET1090.7551
09:39 ET48800.755
09:41 ET72270.7551
09:43 ET11000.75
09:45 ET7450.7501
09:48 ET575020.74999
09:50 ET32600.748
09:52 ET117130.75
09:54 ET99000.7491
09:56 ET253200.75
09:57 ET43300.7573
10:01 ET16000.7573
10:03 ET171740.7593
10:06 ET1500.7593
10:24 ET1710.7592
10:26 ET58090.7546
10:28 ET85080.7546
10:32 ET6710.7501
10:33 ET286160.745
10:35 ET101000.7411
10:37 ET152380.744299
10:39 ET49210.7516
10:42 ET66140.74665
10:44 ET53200.74
10:46 ET1350.746699
10:48 ET24080.74511
10:50 ET138490.754
10:51 ET1000.7526
11:00 ET22200.7519
11:13 ET2920.7519
11:15 ET1290.7518
11:22 ET2000.7517
11:24 ET8000.75
11:29 ET5000.7516
11:33 ET536520.757
11:38 ET4000.759
11:40 ET20000.75555
11:42 ET4030.7573
11:44 ET13350.7581
11:47 ET2200.759
11:49 ET1000.759
11:51 ET9330.7573
11:54 ET6000.757
12:00 ET1030.758
12:02 ET3000.75715
12:03 ET5500.757
12:05 ET125120.75
12:07 ET2330.7494
12:09 ET3300.7435
12:12 ET8060.7456
12:14 ET1330.7461
12:18 ET54870.75
12:23 ET43250.7515
12:27 ET8640.7462
12:32 ET2500.750099
12:36 ET17800.7501
12:39 ET20000.74805
12:41 ET3960.7477
12:50 ET13600.7493
12:56 ET71000.75
01:01 ET3960.7493
01:03 ET3000.7494
01:08 ET13000.7462
01:10 ET1000.74745
01:19 ET47000.7483
01:21 ET5220.7499
01:24 ET13330.7491
01:28 ET20000.749099
01:32 ET1000.7482
01:37 ET4000.74999
01:39 ET10050.749
01:53 ET10000.75
01:57 ET5690.7482
02:00 ET7410.7486
02:04 ET1330.7491
02:08 ET6000.7482
02:09 ET13080.7482
02:11 ET3340.7493
02:13 ET1000.7491
02:20 ET58040.7457
02:40 ET3000.74505
02:42 ET1030.745
02:45 ET10000.745
02:47 ET120990.7472
02:51 ET1500.74465
03:02 ET1000.7411
03:05 ET26440.737
03:07 ET15980.7406
03:09 ET71990.739
03:12 ET43300.737
03:16 ET6800.7354
03:18 ET52780.7387
03:21 ET101580.7387
03:25 ET1000.740099
03:27 ET50930.7401
03:30 ET10000.74
03:36 ET55960.7409
03:38 ET40400.73355
03:39 ET60830.74
03:45 ET65460.7356
03:48 ET9020.7496
03:50 ET13300.745
03:52 ET6960.7401
03:54 ET35000.736
03:56 ET106180.736
03:57 ET12500.7423
03:59 ET45760.7362
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSPRB
Spruce Biosciences Inc
30.3M
-0.6x
---
United StatesJAGX
Jaguar Health Inc
24.9M
0.0x
---
United StatesDRRX
DURECT Corp
23.8M
-0.7x
---
United StatesAWH
Aspira Women's Health Inc
42.6M
-2.0x
---
United StatesSRZN
Surrozen Inc
34.3M
-0.6x
---
United StatesYS
YS Biopharma Co Ltd
162.0M
-1.5x
---
As of 2024-04-14

Company Information

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Contact Information

Headquarters
611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO, CA, United States 94080
Phone
415-655-4168
Fax
302-636-5454

Executives

Executive Chairman of the Board
Michael Grey
President, Chief Financial Officer
Samir Gharib
Chief Executive Officer, Director
Javier Szwarcberg
Chief Medical Officer
Ralph Charlton
Director
Percival Barretto-Ko

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$30.3M
Revenue (TTM)
$10.1M
Shares Outstanding
41.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.51
EPS
$-1.26
Book Value
$1.86
P/E Ratio
-0.6x
Price/Sales (TTM)
3.0
Price/Cash Flow (TTM)
---
Operating Margin
-515.34%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.